Bamifylline

DB13203InvestigationalSmall molecule

Bamifylline is a methylxanthine derivative indicated in the treatment of bronchial asthma and other conditions with bronchospasm. Bamifylline is a selective A1 adenosine receptor antagonist.

Chemical structure of Bamifylline
Mechanism
Curator reviewed · 1 reference
Formula / weight
C20H27N5O3 · 385.468 g/mol (avg)

Resolves to

Compound
UNIIZTY15D026HCAS2016-63-9ChEMBLCHEMBL2110760ChEBI135605
Clinical / RWD
RxNorm18752ATCR03DA08
Structure
InChIKeyVVUYEFBRTFASAH-UHFFFAOYSA-NSMILESCCN(CCO)CCN1C(CC2=CC=CC=C2)=NC2=C1C(=O)N(C)C(=O)N2C
Targets
P30542ADORA1

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
610Drug interactionsStructured to mechanism, not free text
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
15Marketed productsAcross 2 countries and 7 labellers
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Bamifylline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In